Johnson & Johnson

Chairman and CEO Joaquin Duato sets the strategic capital allocation direction, working in coordination with EVP and CFO Joseph Wolk. The corporate treasury and business development teams execute specific venture and strategic investments, often drawing on scientific due diligence from the company's pharmaceutical and medtech divisions. The governance ultimately reflects the broader corporate structure rather than an independent investment committee.

Deal flow originates primarily through Johnson & Johnson's global R&D and commercial networks, which span academic medical centers, biotech incubators, and venture capital relationships built over decades. The company's participation in the World Economic Forum's Global Lighthouse Network also provides visibility into advanced manufacturing and digital health ventures. This sourcing model gives the fund access to pre-institutional rounds that purely financial investors rarely see.

The mandate is dual-use: portfolio companies must meet financial return thresholds while holding credible strategic value to Johnson & Johnson's pharmaceutical, medical device, or consumer health divisions. Many venture positions serve as options on future acquisitions, technology licensing deals, or manufacturing partnerships. This makes the fund a corporate venture capital vehicle in function, even where it operates under the pension fund's legal structure.

The fund concentrates on venture-stage and early-growth companies, typically from Series A through late-stage venture rounds prior to IPO. It also participates in select structured financings for more mature private companies developing technologies adjacent to Johnson & Johnson's core therapeutic areas, such as surgical robotics, cell therapy manufacturing, and AI-driven diagnostics.

No. The Robert Wood Johnson Foundation is an independent philanthropic entity that received Johnson & Johnson stock from the founder's estate but operates entirely separately from the corporation and its pension fund. The foundation has its own investment office and governance, focused on public health grantmaking in the United States.

Johnson & Johnson holds significant industrial real estate directly on its corporate balance sheet, including biologics manufacturing campuses in Wilson, North Carolina and cell therapy facilities in Lansdale, Pennsylvania, plus a global manufacturing portfolio. These assets serve operational purposes — producing commercial pharmaceuticals and medical devices — rather than functioning as third-party income properties. The corporate art program and a registered corporate jet are additional non-securities holdings.

Johnson & Johnson routinely co-invests alongside leading life sciences venture capital firms, particularly those with deep domain expertise in biotechnology, medical devices, and digital health. The company participates in syndicated venture rounds and occasionally acts as a follow-on strategic investor in rounds led by financial VCs, leveraging its balance sheet to provide portfolio companies with both capital and commercialization pathways.